Sarepta Therapeutics stock: Piper Sandler keeps Hold rating
Published on 11/17/2026 at 13:42 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target and market context
- Piper Sandler analyst Biren Amin maintained a Hold rating and set a USD 20 price target.
- The analyst consensus cited by TipRanks was Hold with an average target of USD 21.53.
- Deutsche Bank had upgraded Sarepta to Hold with an USD 18 target on November 10.
Piper Sandler analyst Biren Amin maintained a Hold rating on Sarepta Therapeutics and set a USD 20 price target on Friday, November 13, according to Markets Insider, which cited TipRanks.
Sarepta Therapeutics stock traded at 13.91 euros on Lang & Schwarz at 13:34 CET on Tuesday, November 17.
Analyst target and market context
The report said the analyst consensus was Hold with an average price target of USD 21.53. Deutsche Bank had upgraded Sarepta to Hold with an USD 18 target in a report issued on November 10.
The company reported third-quarter results on November 5. It cited third-quarter net product revenue of approximately USD 323.8 million and said multiple ascending dose data from its SRP-1003 and SRP-1001 programs were expected in the fourth quarter.
Sarepta Therapeutics
- ISIN: US8036071004
- Ticker: SRPT
- Primary exchange: Nasdaq
- Lang & Schwarz quote: 13.91 euros on November 17, 2026, at 13:34 CET
- Analyst action: Piper Sandler maintained Hold and set a USD 20 price target on November 13, 2026
Sarepta trades on Nasdaq, linking its market context to the Nasdaq Composite.
